{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T14:11:36Z","timestamp":1774793496647,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/cji.0b013e31816a812d","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T18:44:56Z","timestamp":1236192296000},"page":"377-384","source":"Crossref","is-referenced-by-count":40,"title":["Efficient Adenovector CD40 Ligand Immunotherapy of Canine Malignant Melanoma"],"prefix":"10.1097","volume":"31","author":[{"given":"Henrik","family":"von Euler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arian","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricio","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Segall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Korsgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"T\u00f6tterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210219","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1354\/vp.39-6-651","article-title":"A comparative review of melanocytic neoplasms","volume":"39","author":"Smith","year":"2002","journal-title":"Vet Pathol"},{"key":"R2-6-20210219","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.2460\/ajvr.1987.48.11.1642","article-title":"Biologic characterization of canine melanoma cell lines","volume":"48","author":"Wolfe","year":"1987","journal-title":"Am J Vet Res"},{"key":"R3-6-20210219","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1939-1676.2003.tb02513.x","article-title":"The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects","volume":"17","author":"Sulaimon","year":"2003","journal-title":"J Vet Intern Med"},{"key":"R4-6-20210219","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1354\/vp.39-4-458","article-title":"Expression and significance of p53, rb, p21\/waf-1, p16\/ink-4a, and PTEN tumor suppressors in canine melanoma","volume":"39","author":"Koenig","year":"2002","journal-title":"Vet Pathol"},{"key":"R5-6-20210219","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcpa.2003.10.006","article-title":"Differential expression of CD44 in canine melanocytic tumours","volume":"130","author":"Serra","year":"2004","journal-title":"J Comp Pathol"},{"key":"R6-6-20210219","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/02841860410031372","article-title":"Primary malignant melanoma of the vulva\u2014an aggressive tumor for modeling the genesis of non-UV light-associated melanomas","volume":"43","author":"Ragnarsson-Olding","year":"2004","journal-title":"Acta Oncol"},{"key":"R7-6-20210219","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1292\/jvms.64.169","article-title":"Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines","volume":"64","author":"Ohashi","year":"2002","journal-title":"J Vet Med Sci"},{"key":"R8-6-20210219","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2460\/ajvr.2003.64.544","article-title":"Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs","volume":"64","author":"Catchpole","year":"2003","journal-title":"Am J Vet Res"},{"key":"R9-6-20210219","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI510","article-title":"In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma","volume":"101","author":"Dow","year":"1998","journal-title":"J Clin Invest"},{"key":"R10-6-20210219","first-page":"4249","article-title":"Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor","volume":"5","author":"MacEwen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R11-6-20210219","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0039-6109(05)70519-3","article-title":"Medical treatment of metastatic melanoma","volume":"76","author":"Houghton","year":"1996","journal-title":"Surg Clin North Am"},{"key":"R12-6-20210219","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/1097-0142(19931115)72:10<3091::AID-CNCR2820721034>3.0.CO;2-V","article-title":"Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis","volume":"72","author":"Sirott","year":"1993","journal-title":"Cancer"},{"key":"R13-6-20210219","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/030098587901600103","article-title":"Prognosis after surgical excision of canine melanomas","volume":"16","author":"Bostock","year":"1979","journal-title":"Vet Pathol"},{"key":"R14-6-20210219","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2460\/javma.1981.178.06.580","article-title":"Prognostic criteria for dogs with oral melanoma","volume":"178","author":"Harvey","year":"1981","journal-title":"J Am Vet Med Assoc"},{"key":"R15-6-20210219","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/07357908609017520","article-title":"Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum","volume":"4","author":"MacEwen","year":"1986","journal-title":"Cancer Invest"},{"key":"R16-6-20210219","first-page":"1284","article-title":"Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial","volume":"9","author":"Bergman","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R17-6-20210219","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1357-4310(96)20031-0","article-title":"Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans","volume":"3","author":"Knapp","year":"1997","journal-title":"Mol Med Today"},{"key":"R18-6-20210219","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00046339","article-title":"Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment","volume":"9","author":"MacEwen","year":"1990","journal-title":"Cancer Metastasis Rev"},{"key":"R19-6-20210219","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3109\/07357900009012210","article-title":"Spontaneously occurring tumors of companion animals as models for human cancer","volume":"18","author":"Vail","year":"2000","journal-title":"Cancer Invest"},{"key":"R20-6-20210219","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.cgt.7700507","article-title":"In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154","volume":"9","author":"Loskog","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"R21-6-20210219","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(05)65928-9","article-title":"Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer","volume":"166","author":"Loskog","year":"2001","journal-title":"J Urol"},{"key":"R22-6-20210219","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.4049\/jimmunol.172.11.7200","article-title":"Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment","volume":"172","author":"Loskog","year":"2004","journal-title":"J Immunol"},{"key":"R23-6-20210219","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/1078-0432.CCR-05-1817","article-title":"AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model","volume":"11","author":"Loskog","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R24-6-20210219","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"R25-6-20210219","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187153007780059432","article-title":"CD40L\u2014a multipotent molecule for tumor therapy","volume":"7","author":"Loskog","year":"2007","journal-title":"Endocr Metabol Immune Disord Drug Targets"},{"key":"R26-6-20210219","article-title":"TNM Classification of Tumours in Domestic Animals","author":"Owen","year":"1980"},{"key":"R27-6-20210219","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-005-0051-4","article-title":"Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1\/Th3 dominated tumors","volume":"55","author":"Loskog","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"R28-6-20210219","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"R29-6-20210219","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"R30-6-20210219","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1016\/j.vaccine.2005.08.027","article-title":"Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center","volume":"24","author":"Bergman","year":"2006","journal-title":"Vaccine"},{"key":"R31-6-20210219","first-page":"8","article-title":"Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma","volume":"6","author":"Liao","year":"2006","journal-title":"Cancer Immun"},{"key":"R32-6-20210219","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00262-003-0387-6","article-title":"Intralesional lipid-complexed cytokine\/superantigen immunogene therapy for spontaneous canine tumors","volume":"52","author":"Thamm","year":"2003","journal-title":"Cancer Immunol Immunother"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CJI.0b013e31816a812d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:22:38Z","timestamp":1738974158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002371-200805000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31816a812d","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}